Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 5, 2012, Pages 852-863

  Riegger, C ^a,b   Herrmann, J ^b   Nagarajah, J ^b   Hecktor, J ^b   Kuemmel, S ^b   Otterbach, F ^b   Hahn, S ^b   Bockisch, A ^b   Lauenstein, T ^b   Antoch, G ^a   Heusner, T A ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Multimodality imaging algorithm; PET CT; Primary breast cancer; Staging

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GADOBUTROL; IOBITRIDOL; IOPROMIDE; MEDRONATE TECHNETIUM TC 99M;

ADULT; AGED; ALGORITHM; APOCRINE CARCINOMA; ARTICLE; AXILLARY LYMPH NODE; BONE LESION; BONE SCINTISCANNING; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; COLORECTAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; INTRADUCTAL CARCINOMA; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MICROPAPILLARY CARCINOMA; MUCINOUS CARCINOMA; PAPILLARY CARCINOMA; PREDICTIVE VALUE; PRIMARY TUMOR; RADIOGRAPHY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; TUBULAR CARCINOMA; TUMOR ABLATION; WHOLE BODY CT; WHOLE BODY PET;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

EID: 84862576001     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2077-0     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Kataja V, Castiglione M. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:10-4.
3. Kreienberg R, Kopp I, LorenzW, BudachW, Dunst J, Lebeau A, et al. Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau. Informationszentrum für Standards in der Onkologie. Berlin: Deutsch Krebsgesellschaft; 2004. p. 2-172.
4. Kreienberg R, Kopp I, Albert U, Bartsch HH, Beckmann MW, Berg D, et al. Interdisciplinary S3 guidelines for the diagnosis, treatment and follow-up care of breast cancer. 1st updated version. Germering: Zuckschwerdt; 2008. p. 1-308.
5. Ganz PA. Psychological and social aspects of breast cancer. Oncology (Williston Park). 2008;22:642-6, 650; discussion 650, 653.
6. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med. 2004;45 Suppl 1:56S-65S.
7. Kuehl H, Antoch G. How much CT do we need for PET/CT? A radiologist's perspective. Nuklearmedizin. 2005;44 Suppl 1:S24-31.
8. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol. 2009;70:382-92.
9. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360-85.
10. Groheux D, Moretti JL, Giacchetti S, Hindie E, Teyton P, Cuvier C, et al. PET/CT in breast cancer: an update. Bull Cancer. 2009;96:1053-70.
11. Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543-50.
12. Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, Quinsten A, et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for wholebody breast cancer staging. Eur J Nucl Med Mol Imaging. 37:1077-86.
13. Dalus K, Rendl G, Rettenbacher L, Pirich C. FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging. 2010;37:1992-3
14. Constantinidou A, Martin A, Sharma B, Johnston SR. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol. 2011;22:307-14.
15. Heusner TA, Freudenberg LS, Kuehl H, Hauth EA, Veit-Haibach P, Forsting M, et al. Whole-body PET/CT-mammography for staging breast cancer: initial results. Br J Radiol. 2008;81:743-8.
16. Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, et al. Breast cancer staging in a single session: wholebody PET/CT mammography. J Nucl Med. 2008;49:1215-22.
17. Groheux D, Hindie E, Rubello D, Espie M, Baillet G, Giacchetti S, et al. Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging. 2009;36:1539-42.
18. Antoch G, Kuehl H, Kanja J, Lauenstein TC, Schneemann H, Hauth E, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology. 2004;230:879-85.
19. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-4.
20. Faverly DR, Burgers L, Bult P, Holland R. Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol. 1994;11:193-8.
21. Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008;71:695-704.
22. Jacobs MA, Ouwerkerk R, Wolff AC, Gabrielson E, Warzecha H, Jeter S, et al. Monitoring of neoadjuvant chemotherapy using multiparametric, (23)Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat. 2011;128:119-26.
23. Champion L, Brain E, Giraudet A-L, Le Stanc E, Wartski M, Edeline V, et al. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer. 2011;117:1621-9.
24. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer. 2006;107:2545-51.
25. Filippi V, Malamitsi J, Vlachou F, Laspas F, Georgiou E, Prassopoulos V, et al. The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nucl Med Commun. 2011;32:85-90.
26. Aukema TS, Rutgers EJ, Vogel WV, Teertstra HJ, Oldenburg HS, Vrancken Peeters MT, et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol. 2010;36:387-92.
27. Niikura N, Liu J, Costelloe CM, Palla SL, Madewell JE, Hayashi N, et al. Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer. Oncologist. 2011;16:772-82.
28. Alberini JL, Lerebours F,WartskiM, Fourme E, Le Stanc E, Gontier E, et al. 18F-fluorodeoxyglucose positron emission tomography/ computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer. 2009;115:5038-47.
29. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009;50:231-8.
30. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008;109:417-26.
31. Rousseau C, Devillers A, Campone M, Campion L, Ferrer L, Sagan C, et al. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Eur J Nucl Med Mol Imaging. 2011;38:1029-36.
32. Ueda S, Tsuda H, Saeki T, Osaki A, Shigekawa T, Ishida J, et al. Early reduction in standardized uptake value after one cycle of neoadjuvant chemotherapy measured by sequential FDG PET/CT is an independent predictor of pathological response of primary breast cancer. Breast J. 2010;16:660-2.
33. Groheux D, Giacchetti S, Espie M, Rubello D, Moretti J-L, Hindie E. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging. 2011;38:419-25.
34. Suga K, Kawakami Y, Hiyama A, Matsunaga N. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan. Ann Nucl Med. 2009;23:399-407.
35. Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer. 2008;8:165.
36. Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166-70.
37. Kuhl CK. Breast MR imaging at 3T. Magn Reson Imaging Clin N Am. 2007;15:315-20. vi.
38. Heusner TA, Hahn S, Jonkmanns C, Kuemmel S, Otterbach F, Hamami ME, et al. Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: initial results. Br J Radiol. 2011;84:126-35.
39. VeronesiU,Viale G, Paganelli G, Zurrida S, LuiniA, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595-600.
40. Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001;19:628-33.
41. Veronesi U, Marubini E, Del Vecchio M, Manzari A, Andreola S, Greco M, et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst. 1995;87:19-27.
42. Broet P, de la Rochefordiere A, Scholl SM, Fourquet A, De Rycke Y, Pouillart P, et al. Analyzing prognostic factors in breast cancer using a multistate model. Breast Cancer Res Treat. 1999;54:83-9.
43. Fuster D, Duch J, Paredes P, Velasco M, Munoz M, Santamaria G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746-51.
44. Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyogg J. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med. 2010;51:401-12.
45. Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med. 2001;42:1334-7.
46. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253-8.